Gender differences in outcomes of patients with cystic fibrosis.

BACKGROUND Cystic fibrosis (CF) is a common life-shortening genetic disease in which women have been described to have worse outcomes than males, particularly in response to respiratory infections with Pseudomonas aeruginosa. However, as advancements in therapies have improved life expectancy, this gender disparity has been challenged. The objective of this study is to examine whether a gender-based survival difference still exists in this population and determine the impact of common CF respiratory infections on outcomes in males versus females with CF. METHODS We conducted a retrospective cohort analysis of 32,766 patients from the United States Cystic Fibrosis Foundation Patient Registry over a 13-year period. Kaplan-Meier and Cox proportional hazards models were used to compare overall mortality and pathogen based survival rates in males and females. RESULTS Females demonstrated a decreased median life expectancy (36.0 years; 95% confidence interval [CI] 35.0-37.3) compared with men (38.7 years; 95% CI 37.8-39.6; p<0.001). Female gender proved to be a significant risk factor for death (hazard ratio 2.22, 95% CI 1.79-2.77), despite accounting for variables known to influence CF mortality. Women were also found to become colonized earlier with several bacteria and to have worse outcomes with common CF pathogens. CONCLUSIONS CF women continue to have a shortened life expectancy relative to men despite accounting for key CF-related comorbidities. Women also become colonized with certain common CF pathogens earlier than men and show a decreased life expectancy in the setting of respiratory infections. Explanations for this gender disparity are only beginning to be unraveled and further investigation into mechanisms is needed to help develop therapies that may narrow this gender gap.

[1]  Shih-Yin Chen,et al.  Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. , 2014, The Lancet. Respiratory medicine.

[2]  Jie Zheng,et al.  Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men , 2014, Pediatric pulmonology.

[3]  D. Rodgers,et al.  Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  S. Brody,et al.  Sex hormone-dependent regulation of cilia beat frequency in airway epithelium. , 2012, American journal of respiratory cell and molecular biology.

[5]  N. McElvaney,et al.  Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis , 2012, Expert review of respiratory medicine.

[6]  J. Britton,et al.  Are measures of body habitus associated with mortality in cystic fibrosis? , 2012, Chest.

[7]  J. Moss,et al.  Optimizing treatments for lymphangioleiomyomatosis , 2012, Expert review of respiratory medicine.

[8]  B. Dimitrov,et al.  Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. , 2012, The New England journal of medicine.

[9]  Xiaoxi Ma,et al.  Clinical care guidelines for cystic fibrosis-related diabetes , 2012 .

[10]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[11]  B. Assael,et al.  Absence of a gender gap in survival. An analysis of the Italian registry for cystic fibrosis in the paediatric age. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  S. Doucette,et al.  Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis , 2011, Thorax.

[13]  B. Wildman,et al.  Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis , 2011, Pediatric pulmonology.

[14]  P. Calverley,et al.  Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. , 2010, American journal of respiratory and critical care medicine.

[15]  K. Robinson,et al.  Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes , 2010, Diabetes Care.

[16]  Yufa Wang,et al.  Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice , 2010, Respiratory research.

[17]  J. Nick,et al.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. , 2010, American journal of respiratory and critical care medicine.

[18]  W. Thomas,et al.  17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. , 2010, American journal of respiratory and critical care medicine.

[19]  C. Merlo,et al.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. , 2010, JAMA.

[20]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[21]  Parinya Chamnan,et al.  Diabetes as a Determinant of Mortality in Cystic Fibrosis , 2009, Diabetes Care.

[22]  D. Laskowski,et al.  Effects of the menstrual cycle on lung function variables in women with asthma. , 2009, American journal of respiratory and critical care medicine.

[23]  Seiko F. Okada,et al.  17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. , 2008, The Journal of clinical investigation.

[24]  M. Raffeld,et al.  Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. , 2008, American journal of respiratory and critical care medicine.

[25]  Meilan K. Han,et al.  Gender and chronic obstructive pulmonary disease: why it matters. , 2007, American journal of respiratory and critical care medicine.

[26]  S. Rich,et al.  A USA-based registry for pulmonary arterial hypertension: 1982–2006 , 2007, European Respiratory Journal.

[27]  D. Yates,et al.  Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. , 2007, Scandinavian journal of work, environment & health.

[28]  E. Halm,et al.  Sex differences in lung cancer survival: do tumors behave differently in elderly women? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Cerfolio,et al.  Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. , 2006, Chest.

[30]  J. P. Singh,et al.  TREATMENT OUTCOME OF TUBERCULOSIS UNDER DIRECTLY OBSERVED TREATMENT SHORT COURSE (DOTS) IN PATIENTS PRESENTING AT CHEST TB HOSPITAL, AMRITSAR , 2005 .

[31]  N. Verma,et al.  Is there still a gender gap in cystic fibrosis? , 2005, Chest.

[32]  B. Morrissey,et al.  Bronchiectasis: sex and gender considerations. , 2004, Clinics in chest medicine.

[33]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[34]  J. Norris,et al.  Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening , 2003, Pediatric pulmonology.

[35]  A. Callegaro,et al.  Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. , 2002, American journal of epidemiology.

[36]  K. Suzuki,et al.  Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice , 2001, Clinical and experimental immunology.

[37]  T. Liou,et al.  Predictive 5-year survivorship model of cystic fibrosis. , 2001, American journal of epidemiology.

[38]  J. Katzenellenbogen,et al.  Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated chloride secretion. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  M S Pepe,et al.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.

[40]  M. Rosenfeld,et al.  Gender gap in cystic fibrosis mortality. , 1997, American journal of epidemiology.

[41]  N. Sweezey,et al.  Sex hormones regulate CFTR in developing fetal rat lung epithelial cells. , 1997, The American journal of physiology.

[42]  M. Corey,et al.  Determinants of mortality from cystic fibrosis in Canada, 1970-1989. , 1996, American journal of epidemiology.

[43]  P. J. Byard,et al.  Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. , 1995, Journal of clinical epidemiology.

[44]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[45]  S. Fitzsimmons.  The changing epidemiology of cystic fibrosis. , 1994, Current problems in pediatrics.